Reviewer's report
Title:The role of aspirin in post-polypectomy bleeding a retrospective survey
Version: 2Date:26 March 2012
Reviewer: Lukejohn Day
Reviewer's report:
1. What are the characteristics of the participating hospitals? Volume of
colonoscopies performed?
2. Does the authors’ endoscopy unit follow a protocol for patients taking ASA or
NSAIDs (similar to the one described for Coumadin)? Or is is physician
dependent?
3. Could patients obtain healthcare at other hospitals outside of the ones
included in the study? For example if a patient developed symptoms of a LGIB
could they have sought care at other institutions that were not captured in the
study.
4. What predictors were examined to see if they were associated with
post-polypectomy bleeding?
5. What was the distribution of common indications for colonoscopy among the
study population?
6. Table 2 could be eliminated
7. A table looking at all of the examined factors associated with post-polypectomy
bleeding should be included.
8. Do we know the outcomes of the patients who had a post-polypectomy bleed?
For example, length of hospitalization, transfusion requirement, deaths. Also a
comparison of outcomes from post-polypectomy bleeding of ASA and non-ASA
patients would be very useful data.
9. Were comorbid medical conditions of the study population examined as a
predictor of bleeding? Some studies suggest that increased comorbidity
increases the risk for post-polypectomy bleeding.
10. Did the authors look at specific dosing of ASA to see if this was associated
with increased rates of post-polypectomy bleeding?
11. The authors focus a significant amount on primary and secondary prevention
with respect to ASA and cardiovascular disease in the discussion, this could be
shortened.
12. A number of studies have suggested that ASA does not increase the rate of
post-polypectomy bleeding (Yousfi et al; Am J Gastroenterol. 2004
Sep;99(9):1785-9 and Hui et al; Gastrointest Endosc. 2004 Jan;59(1):44-8).
These articles (and how the current study is different or improves upon them)
should be discussed.
13. Another limitation is that patients may have sought care elsewhere for their
post-polypectomy bleed thereby underestimating the effect of bleeding. This
should be discussed.
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
None
Reviewer's report
Title:The role of aspirin in post-polypectomy bleeding a retrospective survey
Version: 2Date:26 March 2012
Reviewer: Lukejohn Day
Reviewer's report:
1. What are the characteristics of the participating hospitals? Volume of
colonoscopies performed?
2. Does the authors’ endoscopy unit follow a protocol for patients taking ASA or
NSAIDs (similar to the one described for Coumadin)? Or is is physician
dependent?
3. Could patients obtain healthcare at other hospitals outside of the ones
included in the study? For example if a patient developed symptoms of a LGIB
could they have sought care at other institutions that were not captured in the
study.
4. What predictors were examined to see if they were associated with
post-polypectomy bleeding?
5. What was the distribution of common indications for colonoscopy among the
study population?
6. Table 2 could be eliminated
7. A table looking at all of the examined factors associated with post-polypectomy
bleeding should be included.
8. Do we know the outcomes of the patients who had a post-polypectomy bleed?
For example, length of hospitalization, transfusion requirement, deaths. Also a
comparison of outcomes from post-polypectomy bleeding of ASA and non-ASA
patients would be very useful data.
9. Were comorbid medical conditions of the study population examined as a
predictor of bleeding? Some studies suggest that increased comorbidity
increases the risk for post-polypectomy bleeding.
10. Did the authors look at specific dosing of ASA to see if this was associated
with increased rates of post-polypectomy bleeding?
11. The authors focus a significant amount on primary and secondary prevention
with respect to ASA and cardiovascular disease in the discussion, this could be
shortened.
12. A number of studies have suggested that ASA does not increase the rate of
post-polypectomy bleeding (Yousfi et al; Am J Gastroenterol. 2004
Sep;99(9):1785-9 and Hui et al; Gastrointest Endosc. 2004 Jan;59(1):44-8).
These articles (and how the current study is different or improves upon them)
should be discussed.
13. Another limitation is that patients may have sought care elsewhere for their
post-polypectomy bleed thereby underestimating the effect of bleeding. This
should be discussed.
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
None
Please review this paper.
user
Reviewer's report
Title:The role of aspirin in post-polypectomy bleeding a retrospective survey
Version: 2Date:26 March 2012
Reviewer: Lukejohn Day
Reviewer's report:
1. What are the characteristics of the participating hospitals? Volume of
colonoscopies performed?
2. Does the authors’ endoscopy unit follow a protocol for patients taking ASA or
NSAIDs (similar to the one described for Coumadin)? Or is is physician
dependent?
3. Could patients obtain healthcare at other hospitals outside of the ones
included in the study? For example if a patient developed symptoms of a LGIB
could they have sought care at other institutions that were not captured in the
study.
4. What predictors were examined to see if they were associated with
post-polypectomy bleeding?
5. What was the distribution of common indications for colonoscopy among the
study population?
6. Table 2 could be eliminated
7. A table looking at all of the examined factors associated with post-polypectomy
bleeding should be included.
8. Do we know the outcomes of the patients who had a post-polypectomy bleed?
For example, length of hospitalization, transfusion requirement, deaths. Also a
comparison of outcomes from post-polypectomy bleeding of ASA and non-ASA
patients would be very useful data.
9. Were comorbid medical conditions of the study population examined as a
predictor of bleeding? Some studies suggest that increased comorbidity
increases the risk for post-polypectomy bleeding.
10. Did the authors look at specific dosing of ASA to see if this was associated
with increased rates of post-polypectomy bleeding?
11. The authors focus a significant amount on primary and secondary prevention
with respect to ASA and cardiovascular disease in the discussion, this could be
shortened.
12. A number of studies have suggested that ASA does not increase the rate of
post-polypectomy bleeding (Yousfi et al; Am J Gastroenterol. 2004
Sep;99(9):1785-9 and Hui et al; Gastrointest Endosc. 2004 Jan;59(1):44-8).
These articles (and how the current study is different or improves upon them)
should be discussed.
13. Another limitation is that patients may have sought care elsewhere for their
post-polypectomy bleed thereby underestimating the effect of bleeding. This
should be discussed.
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
None
assistant